The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of sociodemographic factors and Medicaid expansion on postoperative outcomes for glioblastoma, 2004-2021.
 
Bhav Jain
No Relationships to Disclose
 
Pragat Patel
No Relationships to Disclose
 
Gabriela Ruiz Colón
No Relationships to Disclose
 
Lily Kim
No Relationships to Disclose
 
John Choi
No Relationships to Disclose
 
Edward Dee
Other Relationship - NIH/NCI; Prostate Cancer Foundation
 
Tej Azad
No Relationships to Disclose
 
Laura Prolo
No Relationships to Disclose
 
Gordon Li
Research Funding - Novocure
 
Michael Lim
Stock and Other Ownership Interests - Egret Bioscience
Honoraria - Accuray; Agenus; Bristol-Myers Squibb; InSightec; Merck; Oncorus; Stryker; tocagen
Consulting or Advisory Role - Biohaven Pharmaceuticals; Bristol-Myers Squibb; CraniUs; Egret Bioscience; Global Coalition for Adaptive Research; Hemispherian; Hoth Therapeutics; InCephalo Therapeutics/University of Zurich; Insightec; Mediflix; novocure; Noxxon Pharma; Pyramid Biosciences; Sanianoia; SERVIER; Stryker; VBI Vaccines
Research Funding - Accuray (Inst); Arbor Pharmaceuticals (Inst); Biohaven Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - Combination of Immunotherapy with Local Chemotherapy for the Treatment of Malignancies. (Inst); CXCR6 as an Immuno-oncology Target to Improve T cell Metabolic Response (Inst); Meteorin-like (METRNL) as an Immuno-oncology Target (Inst); Methods of Treating Myocardial Infarction, Ischemia, and Ischemia Reperfusion Injury (Inst); Methods Patent for Combining Immunotherapy with Radiation (Inst); Modulation of Oxidative Stress as a Therapeutic Pathway in Trigeminal Neuralgia (Inst); Novel Immunotherapeutic Targets Identified in Patients with Glioblastoma using RNA Sequencing to Compare Gene Expression Patterns in Tumor Infiltrating (TIL) and Peripheral Blood Lymphocytes (Inst); Polyfunctional lymphocytes as a biomarker of antitumor activity (Inst); Post-surgical imaging marker: A marker for imaging includes a bio-dissolvable material and a contrast agent configured to provide contrast during an imaging procedure. (Inst); Program Death 1 (PD-1) Agonists for the Treatment of Cerebral Vasospasm (Inst); Sustained and Localized Antibody and Immunotherapeutic Delivery to Lymph Nodes (Inst); Universal Microport (Inst); Use of Anti-PD-1 Delivery with the Urogen® Polymer to Tumor Draining Lymph Nodes for Treatment of Cancers (Inst); Use of the ZMIZ1 Marker in Directing Treatment and Predicting Survival in Cancer. (Inst)
Travel, Accommodations, Expenses - Accuray; SERVIER; Stryker